Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genscript Biotech ( (HK:1548) ) has shared an update.
Genscript Biotech Corporation announced the grant of 36,314 share awards to two independent non-executive directors under its 2019 RSU Scheme. The awards, which have no purchase price or performance targets, aim to align the directors’ interests with the company’s and its shareholders’ interests, with a vesting period extending over three years.
The most recent analyst rating on (HK:1548) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a company incorporated in the Cayman Islands with limited liability, operating within the biotech industry. The company is listed on the Hong Kong Stock Exchange and is known for its focus on biotechnology products and services.
YTD Price Performance: 37.20%
Average Trading Volume: 10,617,308
Technical Sentiment Signal: Sell
Current Market Cap: HK$29.36B
For an in-depth examination of 1548 stock, go to TipRanks’ Overview page.